US 11,701,385 B2
Modulation of cell function for immunotherapy
Zhiyuan Cao, Shanghai (CN); Chengfei Pu, Shanghai (CN); Lei Xiao, Shanghai (CN); and Zhao Wu, Shanghai (CN)
Assigned to Innovative Cellular Therapeutics Holdings, Ltd., George Town (KY)
Filed by Innovative Cellular Therapeutics Holdings, Ltd., George Town (KY)
Filed on Aug. 29, 2019, as Appl. No. 16/555,198.
Claims priority of provisional application 62/725,895, filed on Aug. 31, 2018.
Prior Publication US 2020/0069732 A1, Mar. 5, 2020
Int. Cl. A61K 35/17 (2015.01); C07K 16/28 (2006.01); C07K 14/725 (2006.01); A61K 47/65 (2017.01); C07K 14/47 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 47/65 (2017.08); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 16/2803 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)] 14 Claims
 
1. A modified cell engineered to express an antigen binding molecule, wherein expression and/or function of CXCR3 in the modified cell has been enhanced, and wherein the modified cell comprises nucleic acid sequence SEQ ID NO: 125.